Results 221 to 230 of about 103,961 (275)

A phase II trial of nivolumab for patients with platinum-refractory recurrent or metastatic salivary gland cancer. [PDF]

Jpn J Clin Oncol
Nagatani Y, Kiyota N, Yamazaki T, Asada Y, Higashino M, Satake H, Boku S, Nishimura A, Uemura H, Ota I, Yane K, Tanaka K, Onoe T, Hirayama Y, Tsujikawa T, Fujiwara H, Shimoda H, Nibu KI, Imamura Y, Kimbara S, Koyama T, Funakoshi Y, Minami H.   +22 more
europepmc   +1 more source

Alveolar Soft Part Sarcoma in Pediatric and Young Adult Patients: A Report From the Children's Oncology Group Study ARST0332

Pediatric Blood &Cancer, Volume 73, Issue 5, May 2026.
ABSTRACT Background Alveolar soft part sarcoma (ASPS) is a rare soft tissue sarcoma occurring most commonly in adolescence and young adulthood. Methods We present the clinical characteristics, treatments, and outcomes of patients with newly diagnosed ASPS enrolled on the Children's Oncology Group study ARST0332.
Jacquelyn N. Crane, Wei Xue, Amira Qumseya, Thomas Scharschmidt, Kathryn R. Tringale, Oscar Lopez Nunez, Jiaqi Hu, Donald A. Barkauskas, Rajkumar Venkatramani, Sheri L. Spunt, Aaron R. Weiss, Noah C. Federman   +11 more
wiley   +1 more source

Deficient mismatch repair/microsatellite instability-high colorectal cancer: current treatment paradigms, limitations and future perspectives. [PDF]

BMJ Oncol
Storandt MH, Sinicrope FA.
europepmc   +1 more source

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

Molecular Oncology, Volume 20, Issue 5, Page 1161-1184, May 2026.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung, David Bickel, Lena C. M. Krause, Daria Ezeriņa, Christian Ickes, Julian Wojtachnia, Christine S. Gibhardt, Magdalena Shumanska, Khadija Wahni, Andrea Paluschkiwitz, Julia Malo Pueyo, Ekaterina Baranova, Wim Vranken, Hedwig Stanisz, Ioana Stejerean‐Todoran, Michael P. Schön, Joris Messens, Ivan Bogeski   +17 more
wiley   +1 more source

Prognostic Impact of the Lung Immune Prognostic Index in Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab. [PDF]

Cancers (Basel)
Bedir Ş, Kapağan T, Bozkaya Y, Oyman A, Fidan MC, Guliyev M, Abbasov H, Demirci NS, Yıldırım Doğan HG, Çelik E, Bulut N, Erdem GU.   +11 more
europepmc   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, Volume 20, Issue 5, Page 1220-1236, May 2026.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743. [PDF]

J Clin Oncol
Scherpereel A, Baas P, Nowak AK, Tsao AS, Fujimoto N, Peters S, Mansfield AS, Popat S, Bautista Aragon Y, Talbot T, Grossi F, Kowalski D, Kaplan MA, Cardona AF, Soomro R, Hu N, Lee A, Ip V, Hung YH, Zalcman G.   +19 more
europepmc   +1 more source

Immune Checkpoint Inhibitors and Immunomodulators for Cancer Immunotherapy: Insights Into Resistance and Therapeutic Strategies

Advanced Science, Volume 13, Issue 25, 4 May 2026.
The schematic diagram illustrates the roles of novel immune checkpoints, immunomodulatory factors, cell death and multimodal technologies in cancer immunotherapy. Abstract Cancer immunotherapy has redefined cancer treatment. However, the molecular and cellular basis of immune evasion and therapeutic resistance remains incompletely understood.
Fangquan Chen, Yang Yu, Xiutao Cai, Junhao Lin, Ruirui Liang, Rui Kang, Daolin Tang, Jiao Liu   +7 more
wiley   +1 more source

ERRATUM: Nutritional status and prognosis in metastatic colorectal cancer: a cohort study. [PDF]

Rev Assoc Med Bras (1992)
Soares Júnior JM.
europepmc   +1 more source

Urinary microbiota diversity and composition in patients with advanced renal cell cancer

BJUI Compass, Volume 7, Issue 5, May 2026.
Abstract Objectives This study aims to investigate the role of urinary microbiota in renal cell carcinoma; we analysed urinary microbiota in kidney cancer patients and explored its potential role as biomarker. Subjects and methods Samples were collected from 49 males (28 patients planned to undergo systemic therapy and 21 healthy volunteers).
Frederico Leal, Romualdo Morandi Filho, Lilian T. Inoue, Vitor Heidrich, Ernande X. dos Santos, Diogo A. Bastos, Anamaria A. Camargo, Denis L. F. Jardim   +7 more
wiley   +1 more source